Study protocol for a randomised trial of nicotine free cigarettes as an adjunct to usual NRT-based cessation practice, in people who wish to stop smoking

Walker, Natalie K.; Howe, Colin; Bullen, Chris; Grigg, Michele; Glover, Marewa; McRobbie, Hayden; Laugesen, Murray; Hoorn, Stephen Vander; Whittaker, Robyn
January 2011
BMC Public Health;2011, Vol. 11 Issue 1, p1
Academic Journal
Background: Current smoking cessation treatments focus on addressing the pharmacological dependence of smokers on nicotine. However, new strategies are needed that address both nicotine dependence and the psychological dependence on cigarettes as the source of nicotine. Evidence from a number of small smoking cessation studies suggests that the use of cigarettes with reduced nicotine content, in combination with nicotine replacement therapy (NRT), may help reduce withdrawal symptoms and increase quit rates. This paper describes the protocol for a large randomised-controlled trial to test the effect of using nicotine-free cigarettes together with NRT on long-term quit rates. Methods/design: This single-blind, randomised trial aims to recruit 1,410 participants through the national telephone-based Quitline service in New Zealand. Participants in the treatment arm will be asked to stop smoking nicotine-containing cigarettes on their chosen Quit day and smoke ad libitum nicotine-free (Quest 3) cigarettes for six weeks. At the same time people in this group will be asked to start using NRT patches, gum and/or lozenges (as recommended by Quitline) for eight weeks. Participants in the control arm will be asked to stop smoking completely on their chosen Quit day and start using NRT patches, gum and/or lozenges (as recommended by Quitline) for eight weeks. Data collection will occur at baseline, three and six weeks, and three and six months after Quit day. The primary outcome is the proportion of participants who self-report seven-day point prevalence abstinence at six months since Quit date. Discussion: Smoking prevalence in New Zealand has changed little in recent years (particularly in Maori, the indigenous people of New Zealand) and additional options for smokers who want to quit are needed. Although a variety of methods are available to help, many are expensive, have side effects, and despite their use most quit attempts still fail. This trial will test the balance of benefits and risks of a new strategy for people to overcome nicotine dependence. Since smoking is the leading cause of lost healthy life years in New Zealand, if proven effective this strategy is likely to have substantial public health benefits. Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12608000410358


Related Articles

  • Development of Procedures for Early Screening of Smoking Cessation Medications in Humans. Perkins, KA; Lerman, C; Stitzer, ML; Fonte, CA; Briski, JL; Scott, JA; Chengappa, KNR // Clinical Pharmacology & Therapeutics;Aug2008, Vol. 84 Issue 2, p216 

    Candidate medications for smoking cessation may be screened more efficiently if initial evaluations in humans combine the practical advantages of laboratory studies with the clinical validity of clinical trials, such as by increasing participants' “quit motivation” during brief...

  • Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. Kralikova, Eva; Kozak, Jiri T.; Rasmussen, Thomas; Gustavsson, Gunnar; Le Houezec, Jacques // BMC Public Health;2009, Vol. 9 Issue 1, p433 

    Background: Even with effective smoking cessation medications, many smokers are unable to abruptly stop using tobacco. This finding has increased interest in smoking reduction as an interim step towards complete cessation. Methods: This multi-center, double-blind placebo-controlled study...

  • Cutting the last cigarette: Are we ready to give patients the perfect solution? Diamantouros, Artemis // Canadian Pharmacists Journal;May/Jun2010, Vol. 143 Issue 3, p148 

    The article explores a study entitled "A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies," by M. E. Piper and colleagues. According to the study, nicotine patch plus lozenge group had the strongest support, with an odds ratio (OR) of 2.34. The study...

  • EDITORIAL. Hrubá, Drahoslava // Central European Journal of Public Health;2012, Vol. 20 Issue 1, p3 

    An introduction to the journal is presented which discusses various reports published within the issue, including one on toxicological methods and variations in nicotine yields in particular cigarettes, one on variability in lead and arsenic content in tobacco and cigarettes and another on...

  • An experimental test of the influence of prior cigarette smoking abstinence on future abstinence. Heil, Sarah H.; Alessi, Sheila M.; Lussier, Jennifer Plebani; Badger, Gary J.; Higgins, Stephen T. // Nicotine & Tobacco Research;Jun2004, Vol. 6 Issue 3, p471 

    Significant positive associations between early and later abstinence are often reported in clinical trials on smoking cessation, but those relationships do not permit causal inferences. The present study was conducted to examine experimentally whether prior smoking abstinence histories can...

  • Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. Yudkin, Patricia; Hey, Kate; Murphy, Michael; Roberts, Sarah; Welch, Sarah; Walton, Robert // BMJ: British Medical Journal (International Edition);7/5/2003, Vol. 327 Issue 7405, p28 

    Discusses abstinence from smoking eight years after participation in randomised controlled trial of the nicotine patch. Lack of studies that investigate abstinence beyond three years; Participants, methods, results; Lack of effectiveness of the patch; Need for more effective ways to help people...

  • Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Caldwell, Brent; Burgess, Carl; Crane, Julian // Nicotine & Tobacco Research;Feb2010, Vol. 12 Issue 2, p179 

    Introduction:: Novel approaches to nicotine replacement therapy (NRT) are needed to improve the modest long-term quit rate of 10%. Snus (Swedish tobacco) and Zonnic (oral nicotine sachet) rapidly deliver nicotine via buccal absorption and have potential as NRTs. As a prelude to formal evaluation...

  • Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. Moore, David; Aveyard, Paul; Connock, Martin; Dechao Wang; Fry-Smith, Anne; Barton, Pelham // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/11/2009, Vol. 338 Issue 7699, p867 

    Objective To determine the effectiveness and safety of nicotine replacement therapy assisted reduction to stop' smoking. Design Systematic review of randomised controlled trials. Data sources Cochrane Library, Medline, Embase, CINAHL, PsychlNFO, Science Citation Index, registries of ongoing...

  • 22nd Century Group Announces Initial Results of Smoking Cessation Trial.  // Biomedical Market Newsletter;12/28/2011, Vol. 21, p1 

    The article presents information on the results of a smoking cessation trial conducted by 22nd Century Group Inc. It is stated that a prescription smoking cessation aid namely X-22 that created very low nicotine (VLN) cigarettes led to a decrease in smoking from baseline during the 6-week...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics